Autonomix Medical (NASDAQ: AMIX) shares new pancreatic cancer pain data

Rhea-AI Filing Summary

Autonomix Medical, Inc. furnished an update highlighting new subgroup clinical data from its proof-of-concept study in pancreatic cancer-related pain. The analysis, presented at the 2026 ASCO Gastrointestinal Cancers Symposium, is described as demonstrating rapid, durable and meaningful pain relief in pancreatic cancer patients across all disease stages, expanding on previously reported results from the ongoing evaluation.

The company also posted an updated corporate presentation on its website, which is included as an exhibit. Both the press release and the investor presentation are furnished under a Regulation FD disclosure and are not deemed filed under federal securities laws unless later specifically incorporated by reference.

Insights

Biotech clinical-development analyst

Autonomix highlights new pancreatic cancer pain data and an updated investor deck, but without quantitative details here.

Autonomix Medical reports subgroup results from a proof-of-concept study in pancreatic cancer-related pain, noting rapid, durable and meaningful pain relief across all disease stages. The data were presented at the 2026 ASCO Gastrointestinal Cancers Symposium, which is a recognized venue for gastrointestinal oncology research and can increase scientific and clinical visibility.

The description suggests potentially encouraging clinical activity in pain relief, but this excerpt does not include response rates, durability metrics, or safety outcomes, which are needed to gauge true impact. The company also released an updated corporate presentation, a common way to align investor messaging with new clinical information.

The information is furnished under Regulation FD rather than filed, signaling it is intended as a fair-disclosure communication rather than a change in formal financial reporting. Investors interested in the clinical significance would need to review the full press release and presentation exhibits where the detailed subgroup data and study design are likely described.

false 0001617867 0001617867 2026-01-09 2026-01-09

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 9, 2026

Autonomix Medical, Inc.

(Exact name of registrant as specified in its charter)

Delaware	001-41940	47-1607810
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	(I.R.S. Employer Identification No.)

21 Waterway Avenue, Suite 300

The Woodlands, TX 77380

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (713) 588-6150

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class	Trading Symbol(s)	Name of Each Exchange on which Registered
Common Stock, par value $0.001 per share	AMIX	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.               ☐

Item 7.01. Regulation FD Disclosure

On January 9, 2026, Autonomix Medical, Inc. (the “Company”) issued a press release announcing new subgroup clinical data from its PoC study presented at the 2026 ASCO Gastrointestinal Cancers Symposium demonstrating rapid, durable and meaningful pain relief in pancreatic cancer patients across all disease stages. The analysis expands upon previously reported data from the Company’s ongoing clinical evaluation and examines outcomes by pancreatic cancer stage in patients treated for severe pancreatic cancer-related pain. A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated by reference herein.

Also on January 9, 2026, the Company posted an updated corporate presentation set forth as Exhibit 99.2 herein on the Company’s official website.

The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibits 99.1 and 99.2, are being furnished and shall not be “filed” for the purpose of the Securities Exchange Act of 1934, as amended (“Exchange Act”), nor shall they be incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended (“Securities Act”), unless specifically identified therein as being incorporated by reference.

Item 9.01.  Financial Statements and Exhibits

	(d) Exhibits
	Exhibit No.	Description
	99.1	Press Release dated January 9, 2026
	99.2	Investor Presentation dated January 2026
	104	Cover page Interactive Data File (formatted as Inline XBRL document)

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	AUTONOMIX MEDICAL, INC.
	By:	/s/ Trent Smith
		Trent Smith
		Chief Financial Officer

Dated: January 9, 2026

FAQ

What did Autonomix Medical (AMIX) disclose in this 8-K filing?

Autonomix Medical furnished an update that it issued a press release with new subgroup clinical data from its pancreatic cancer pain proof-of-concept study and posted an updated corporate presentation on its website.

What is the new clinical information Autonomix Medical (AMIX) reported?

The company reported subgroup data from its proof-of-concept study showing rapid, durable and meaningful pain relief in pancreatic cancer patients across all disease stages, based on an analysis of outcomes by cancer stage.

Where were Autonomix Medical's new pancreatic cancer data presented?

The new subgroup clinical data were presented at the 2026 ASCO Gastrointestinal Cancers Symposium, a conference focused on gastrointestinal cancers.

What additional materials did Autonomix Medical (AMIX) release with this update?

Alongside the press release, Autonomix posted an updated corporate investor presentation, which is included as Exhibit 99.2 and made available on the company’s official website.

Are the Autonomix Medical (AMIX) clinical data and presentation considered filed with the SEC?

No. The press release and investor presentation are furnished under Regulation FD and are not deemed filed under the Exchange Act or Securities Act unless a future filing specifically incorporates them by reference.

Does this 8-K contain new financial results for Autonomix Medical (AMIX)?

No. This 8-K focuses on clinical subgroup data and an updated corporate presentation; it does not present new financial statements or earnings data.